V1RI6 Inhibitors
V1RI6 inhibitors are a class of chemical compounds that interact with a very specific biological target, presumably a receptor or enzyme identified by the code V1RI6. The nomenclature suggests that the target has been classified and named according to a systematic approach, likely due to its function or structure. Inhibitors, by definition, are molecules that can bind to a biological molecule and decrease its activity. They often achieve this by attaching to the active site of the target, where the normal biological substrate would bind, thereby preventing the normal action of the target from occurring. V1RI6 inhibitors would be designed to fit into this site with a high degree of specificity, often engaging in various types of non-covalent interactions such as hydrogen bonds, ionic interactions, hydrophobic contacts, and van der Waals forces. The design of these inhibitors is a sophisticated process that requires extensive knowledge of the target's structure and the mechanics behind its function.
In the development of V1RI6 inhibitors, researchers employ various strategies to identify and optimize these compounds. High-throughput screening might be initially used to assay a large library of chemicals for activity against the target V1RI6. Once potential inhibitors are identified, medicinal chemists work to refine the chemical structure to improve specificity and binding affinity. This process often involves the iterative synthesis and testing of analogs - compounds that are structurally similar to initial hits but have been subtly modified to enhance desired properties. The structural biology of the V1RI6 target, including any known three-dimensional structures, can be a critical resource in this endeavor, guiding the design of inhibitors that can interact more effectively with the target. Advanced techniques such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, or cryo-electron microscopy might be used to elucidate the details of how inhibitors bind to V1RI6, providing insights that drive further optimization. Additionally, computational methods like molecular docking and molecular dynamics simulations play an important role in predicting how small molecules might interact with the target and in designing new inhibitors with improved characteristics.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib targets the epidermal growth factor receptor (EGFR) tyrosine kinase domain, which is upstream of several signal transduction pathways. By inhibiting EGFR, downstream signaling through PI3K/AKT/mTOR that might lead to the activation of V1RI6 is suppressed, resulting in its functional inhibition. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib is another EGFR tyrosine kinase inhibitor. It blocks EGFR autophosphorylation and activation, subsequently inhibiting downstream signaling pathways such as RAS/RAF/MEK/ERK that might be involved in the activation of V1RI6, thereby reducing its activity. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Lapatinib inhibits both EGFR and HER2/neu receptors. This dual inhibition is effective at preventing the activation of downstream signaling pathways, including PI3K/AKT/mTOR and RAS/RAF/MEK/ERK, which could contribute to the functional activity of V1RI6. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a multikinase inhibitor that targets RAF kinases, VEGFR, and PDGFR among others. By inhibiting these kinases, Sorafenib disrupts the RAS/RAF/MEK/ERK signaling pathway, which may be critical for V1RI6 activation, thereby diminishing its functional activity. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Sunitinib is a receptor tyrosine kinase inhibitor that affects multiple targets, including PDGFR and VEGFR. This broad inhibition impedes the PI3K/AKT/mTOR pathway, possibly reducing the activity of V1RI6 if it is downstream of these kinases. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $127.00 $178.00 | 2 | |
Pazopanib is a multi-tyrosine kinase inhibitor affecting VEGFR, PDGFR, and c-Kit. By blocking these kinases, pazopanib can potentially inhibit signaling pathways like PI3K/AKT/mTOR and RAS/RAF/MEK/ERK, which in turn may lead to decreased activity of V1RI6. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor with activity against BCR-ABL and SRC family kinases. This inhibition can indirectly lead to the suppression of the RAS/RAF/MEK/ERK pathway, which might be involved in V1RI6 signaling, thus lowering its activity. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $205.00 $405.00 | 9 | |
Nilotinib, a selective inhibitor of BCR-ABL kinase, can also affect other tyrosine kinases. The inhibition of these kinases may attenuate downstream signaling pathways that are pertinent to the activation of V1RI6, such as PI3K/AKT/mTOR, leading to its decreased function. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib targets BCR-ABL, c-Kit, and PDGFR tyrosine kinases. By inhibiting these kinases, imatinib can reduce the activity of downstream signaling pathways such as PI3K/AKT/mTOR and RAS/RAF/MEK/ERK, which may be crucial for the functional activity of V1RI6. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
Trametinib is a MEK inhibitor that specifically inhibits the MEK1/2 kinases within the RAS/RAF/MEK/ERK pathway. This targeted action may prevent the activation of downstream proteins, including V1RI6, thus reducing its functional activity. | ||||||